PRALICIGUAT
Praliciguat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target guanylate cyclase soluble subunit beta-1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 3 | — | — | — | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 2 | — | — | — | 2 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 2 | — | — | — | 2 |
| Heart failure | D006333 | HP_0001635 | I50 | — | 1 | — | — | — | 1 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PRALICIGUAT |
| INN | praliciguat |
| Description | Praliciguat is a member of the class of pyrazoles that is 5-fluoro-2-(1H-pyrazol-3-yl)pyrimidine which is substituted by a 2-fluorobenzyl group at position 1, 1,2-oxazol-3-yl group at position 5, and by a [3,3,3-trifluoro-2-hydroxy-2-(trifluoromethyl)propyl]nitrilo group at position 4. It is a soluble guanylate cyclase stimulator under clinical development for the treatment of heart failure with preserved ejection fraction. It has a role as a soluble guanylate cyclase activator, an anti-inflammatory agent, a vasodilator agent and an antihypertensive agent. It is a member of isoxazoles, a member of pyrazoles, an organofluorine compound, an aminopyrimidine, a tertiary alcohol, a secondary amino compound and a member of monofluorobenzenes. |
| Classification | Small molecule |
| Drug class | guanaline cyclase activators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)(C(F)(F)F)C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 1628730-49-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297214 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | R1S0H458SA (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GUCY1B1
GUCY1B1
Organism
Homo sapiens
Gene name
GUCY1B1
Gene synonyms
GUC1B3, GUCSB3, GUCY1B3
NCBI Gene ID
Protein name
guanylate cyclase soluble subunit beta-1
Protein synonyms
GCS-beta-1, GCS-beta-3, guanylate cyclase 1, soluble, beta 3, Guanylate cyclase soluble subunit beta-3, Soluble guanylate cyclase small subunit
Uniprot ID
Mouse ortholog
Gucy1b1 (54195)
guanylate cyclase soluble subunit beta-1 (O54865)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 121 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use